As Australians await entry to the Moderna vaccine, a examine has highlighted why it’s totally different to the Pfizer vaccine.
Moderna’s vaccine produces twice as many antibodies because the Pfizer-BioNTech vaccine, new analysis has revealed.
Antibody ranges after the second dose of the 2 hottest vaccines within the US had been increased in individuals who had the Moderna shot, in keeping with new analysis revealed within the Journal of the American Medical Association.
In the US, extra than 94 million folks have had each Pfizer-BioNTech vaccines in comparison with 65 million who’ve had each Moderna photographs, in keeping with the Centers for Disease Control and Prevention.
The researchers mentioned the distinction may merely be that the second Moderna vaccine is, on common, administered one week later than the Pfizer vaccine.
The second vaccine of Moderna is usually given 4 weeks after the primary shot, whereas the second Pfizer vaccine is run three weeks following the primary shot.
The examine in contrast the antibody ranges of near 1600 Belgian well being employees, of whom 688 had been vaccinated with Moderna and 959 had Pfizer-BioNTech.
The outcomes confirmed Moderna’s vaccine created twice as many antibodies because the Pfizer-BioNTech vaccine.
But scientists nonetheless have no idea whether or not having extra antibodies means somebody is any much less prone to contract or unfold the virus.
“I would urge caution in making the conclusion that because Moderna demonstrated a slightly higher peak on average that its efficacy will be slower to wane,” Emory University biostatistician David Benkeser advised Bloomberg.
“Such a conclusion requires a host of assumptions that have not yet been evaluated.”
Studies have proven even comparatively low ranges of antibodies are protecting.
This article initially appeared on NY Post and was reproduced with permission